She is right

Cannabis today is like tech 20 years ago, says former Yahoo CEO Carol Bartz



  • Carol Bartz and Joe Montana are among investors who poured $75 million into Caliva, a California-based cannabis company. 
  • Bartz, formerly CEO of Yahoo, said cannabis today is like tech 20 years ago. It has “so much growth potential” and “so many ways to change people’s lives.”
  • Despite some optimists saying federal legalization is right around the corner, Baltz doesn’t think it’ll happen soon.

WATCH NOWVIDEO06:05Cannabis is the new tech, says former Yahoo CEO

Cannabis today is like tech 20 years ago, former Yahoo CEO Carol Bartz told CNBC’s “Squawk Alley” in an interview Thursday after disclosing she had invested in Caliva, a California-based cannabis company,

Bartz and NFL Hall of Famer Joe Montana are among investors who poured $75 million into a fundraising round Caliva announced Thursday. The Silicon-Valley based company manages everything from “seed to sale,” Bartz said. Caliva grows marijuana, makes vape oils and sells products at a San Jose dispensary.

“When I saw this opportunity, I said this is the new world here,” said Bartz, who is also joining Caliva’s board. “It’s like being back in tech 20 years ago. It’s like so much growth potential, so many ways to change people’s lives and so I’m in.”

Some analysts have pointed to CBD, THC’s non-psychoactive cousin, as a huge growth opportunity. The compound can be derived from both the marijuana and the hemp plant. While marijuana remains illegal in most states and federally illegal, the farm bill President Donald Trump signed in December legalized hemp and products derived from it.

Bartz said while CBD is “a very, very important part” of the industry, she thinks the combination of CBD and THC is better. While Bartz is not a smoker, she said she uses cannabis creams on her shoulders and bad knees.

“As it’s legalized in other states, people will understand how important it is to have that combination,” she said.

Despite some optimists saying federal legalization is right around the corner, Baltz doesn’t think it’ll happen soon. In the meantime, though, she thinks Caliva and other companies operating in California will learn a lot “that hopefully will help other people decide to legalize.”

The future of cannabis may not be about getting high.

CBD doesn’t get you high, but could someday eclipse the entire pot industry


The future of cannabis may not be about getting high.

Pot is a multi-billion dollar industry — where it’s legal, anyway — but some advocates believe that the future of cannabis is actually a non-euphoric derivative that delivers health benefits without getting you high.

This past weekend, scores of entrepreneurs, researchers and health advocates congregated in Anaheim, Calif. for CBD Expo West, a conference devoted to showcasing the booming business of CBD, shorthand for Cannabidiol. In California, where adult use of marijuana is permitted, CBD has been showing up in a fast-growing array of products, from vaporizers and oils to skin balms and gummy bears. And you don’t need to duck into a licensed dispensary to buy it; you can often find CBD at your local corner store.

According to the Brightfield Group, sales of CBD are estimated to reach $22 billion by 2022. And after speaking with exhibitors at CBD Expo, it’s easy to see why: They’re passionate advocates of its potential to soothe pain, anxiety and inflammation without need for pharmaceuticals — and without the high of THC, which not everyone wants.

Kyle Turley, a former NFL lineman who now sells a line of CBD products geared at athletes called Neuro XPF, said that cannabis helped him cope with a torturous onset of CTE (chronic traumatic encephalopathy) that appeared during and after his eight-year NFL career. Turley said he’d been prescribed a cocktail of painkillers and other medications to treat a range of symptoms he described as “terrifying,” including disabling vertigo, migraines, rage episodes and eventually suicidal thoughts.

“The things I did under those drugs were insane, and it wasn’t because I abused them,” he recalled. “Cannabis was the thing that worked, and the one thing I always knew helped.” Turley said that over time, he was able to eliminate all other medications in favor of a daily CBD regimen, and believes it could help other athletes more safely manage even common issues like pain.

The fact that CBD doesn’t produce a high isn’t a drawback — it’s one of its biggest selling points.

“The reason people get excited about CBD is that it doesn’t cause euphoria,” said Dr. David Bearman, a physician who has studied the effects of medical marijuana for decades. “People say it’s not psychoactive, which isn’t true — it is both an anti-anxiety drug and antidepressant.”

Many people in the business believe that CBD is a groundbreaking treatment for everything from opiate addiction and depression to PTSD — and that, without the stigma of a federal prohibition such as the one that exists for marijuana, it might be more palatable to the wider public and possibly even to regulators. In June, the FDA approved the first-ever plant-derived CBD drug for two rare forms of epilepsy, called Epidiolex, made by the British drugmaker GW Pharmaceuticals  (GWPH– Get Report) .

But no matter how effective CBD may be as a medical treatment, it’s still part of a complicated and shifting regulatory landscape that’s defined in part by what materials the CBD is derived from — either marijuana plants, which are federally illegal but permitted in some states; or industrial hemp, which is permitted in states that have an approved hemp program.

“There’s been a disconnect in people’s understanding of what’s illegal,” said Michael Chernis, a Los Angeles-based attorney who specializes in cannabis law.

In light of the FDA approval of Epidiolex for example, the DEA has suggested it will re-schedule CBD to take into account both its medical benefits and its potential for abuse. The agency hasn’t done so yet, but Chernis believes that some of the regulatory issues around CBD will be ironed out in the next year.

Despite the current murky legality of cannabis and its extracts, some investors have shown a willingness to dive headfirst into so-called pot stocks, such as Tilray (TLRY) — the medical cannabis producer that saw a wild price spike last week after a bullish interview by CEO Brendan Kennedy on Jim Cramer’s Mad Money CNBC show (Since then, shares have been volatile, with shares up about 15% on Tuesday to $115).

But for anyone aiming to cash in on cannabis right now, legal questions are just one potential cause for caution. Another may be that the industry is simply too new for people to appreciate how different various businesses in it are.

“There are different parts of the space and the supply chain that have different profit margins, challenges, tax consequences — even some of the brand-name retailers you’ve heard of out there aren’t making money,” Chernis noted.

But as demand for CBD grows — and its potential becomes better-understood — there is reason for optimism as well.

“This economy isn’t going away,” Chernis said.

One thought on “CBD doesn’t get you high, but could someday eclipse the entire pot industry”

  1. What’s so bad about getting high? it just means you’re happy, your brain works better, you can focus, you’re more creative, more observant. Your brain hemispheres are in sync, like in meditation. As long as you take small hits and don’t overdose and fall asleep!


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.